CN114028296A - Multi-dimensional skin sensitivity repairing cosmetic component and application - Google Patents
Multi-dimensional skin sensitivity repairing cosmetic component and application Download PDFInfo
- Publication number
- CN114028296A CN114028296A CN202111521355.1A CN202111521355A CN114028296A CN 114028296 A CN114028296 A CN 114028296A CN 202111521355 A CN202111521355 A CN 202111521355A CN 114028296 A CN114028296 A CN 114028296A
- Authority
- CN
- China
- Prior art keywords
- peony root
- extract
- composition
- keratinocytes
- root extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035945 sensitivity Effects 0.000 title claims description 17
- 239000002537 cosmetic Substances 0.000 title abstract description 15
- 241000736199 Paeonia Species 0.000 claims description 60
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 60
- 210000002510 keratinocyte Anatomy 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 29
- 210000003491 skin Anatomy 0.000 claims description 27
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 230000008591 skin barrier function Effects 0.000 claims description 15
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 13
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 13
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229940053128 nerve growth factor Drugs 0.000 claims description 13
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 claims description 13
- 102100028314 Filaggrin Human genes 0.000 claims description 12
- 101710088660 Filaggrin Proteins 0.000 claims description 12
- 102100031784 Loricrin Human genes 0.000 claims description 11
- 108010079309 loricrin Proteins 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102100035435 Ceramide synthase 3 Human genes 0.000 claims description 9
- 101710146188 Ceramide synthase 3 Proteins 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 210000002540 macrophage Anatomy 0.000 claims description 9
- 238000005728 strengthening Methods 0.000 claims description 9
- 206010040830 Skin discomfort Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 102000036181 Fatty Acid Elongases Human genes 0.000 claims description 5
- 108010058732 Fatty Acid Elongases Proteins 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 36
- 238000012360 testing method Methods 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 6
- 102100024304 Protachykinin-1 Human genes 0.000 description 6
- 101800003906 Substance P Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091006084 receptor activators Proteins 0.000 description 5
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- -1 monoterpene glycosides Chemical class 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940015975 1,2-hexanediol Drugs 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100032053 Elongation of very long chain fatty acids protein 4 Human genes 0.000 description 3
- 101000921354 Homo sapiens Elongation of very long chain fatty acids protein 4 Proteins 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000002247 constant time method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000013215 result calculation Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 2
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 230000014537 nerve growth factor production Effects 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- VYZKQGGPNIFCLD-UHFFFAOYSA-N 3,3-dimethylhexane-2,2-diol Chemical compound CCCC(C)(C)C(C)(O)O VYZKQGGPNIFCLD-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 1
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 101000813110 Mus musculus Elongation of very long chain fatty acids protein 6 Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 description 1
- 102000002579 Sphingosine N-acyltransferase Human genes 0.000 description 1
- 108020004714 Sphingosine N-acyltransferase Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 102000003568 TRPV3 Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101150043371 Trpv3 gene Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- CNXJITYCNQNTBD-UHFFFAOYSA-L dipotassium;hexadecyl phosphate Chemical compound [K+].[K+].CCCCCCCCCCCCCCCCOP([O-])([O-])=O CNXJITYCNQNTBD-UHFFFAOYSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 231100000308 non-sensitiser Toxicity 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 150000004669 very long chain fatty acids Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
Abstract
The invention discloses a multi-dimensional cosmetic component for repairing sensitive skin and application thereof.
Description
Technical Field
The invention relates to the field of daily chemical industry, in particular to application of a peony root extract in improving skin sensitivity.
Background
Skin sensitization (sensitive muscle) is a common skin reaction that occurs in women in china at a rate of about 36%. Skin sensitivity is different from skin sensitivity, and allergic reaction is mainly caused by sensitizers, such as coumarin, imidazolidinyl urea, farnesol and the like. Skin sensitivity is primarily the symptoms of skin discomfort caused by non-sensitizers, including stinging, itching, and sometimes redness. The mechanism of sensitive muscle formation is very complex and is currently believed to be due to incomplete skin barrier, excessive neural responses, inflammatory signals, etc.
Although the prior art has been studied for each mechanism of skin sensitivity, attempts have been made to solve the problem by combining ingredients that require complex factors such as compatibility, cooperativity, etc. among the ingredients. Not all active ingredients should be used together, for example, niacinamide and vitamin C, both having good skin care effects, are used together, but rather, niacinamide accelerates the degradation of vitamin C.
There is therefore a great need in the art for substances that can act from multiple mechanical dimensions, improving the problem of skin sensitivity.
Disclosure of Invention
The invention aims to provide a method for repairing sensitive skin in multiple dimensions.
The invention provides application of a peony root extract in preparing a composition for strengthening and/or repairing skin barriers.
In another embodiment, the strengthening and/or repairing the skin barrier comprises promoting the production of filaggrin, loricrin, ceramide synthase3, and/or ultralong chain fatty acid elongase 4 in keratinocytes.
The invention provides application of a peony root extract in preparing a composition for improving skin discomfort.
In another embodiment, the ameliorating skin discomfort comprises reducing inflammatory factors in the skin.
In another embodiment, the improvement in skin discomfort comprises thymic stromal lymphopoietin that inhibits keratinocyte production.
In another embodiment, the ameliorating skin discomfort comprises inhibiting tumor necrosis factor α produced by macrophages.
In another embodiment, the improving skin discomfort comprises inhibiting nerve growth factor production in keratinocytes.
The invention provides application of a peony root extract in preparing a composition for improving skin sensitivity.
In another embodiment, the improvement in skin sensitivity comprises strengthening and/or repairing the skin barrier, reducing inflammatory factors, and having a soothing effect.
In another embodiment, the exerting soothing effect comprises inhibiting nerve growth factor production in keratinocytes.
In another embodiment, the composition comprises 0.01-100 wt% of the extract of peony root, based on the total weight of the composition.
In another embodiment, the composition comprises a peony root extract and a cosmetically acceptable carrier.
In another embodiment, the composition is a dermatological product.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of the peony root extract in the liquid form of the composition is 0.01-3.0 mg/mL.
The present invention provides a method for promoting in vitro production of filaggrin, loricrin, ceramide synthase3, and/or ultralong chain fatty acid elongase 4 in keratinocytes, the method comprising the steps of: mixing the keratinocytes with the extract of peony root.
The present invention provides a method for inhibiting in vitro production of keratinocyte thymic stromal lymphopoietin, and/or inhibiting nerve growth factor produced in keratinocytes, comprising the steps of: mixing the keratinocytes with the extract of peony root.
The invention provides a method for inhibiting tumor necrosis factor alpha generated by macrophages in vitro, which is characterized by comprising the following steps: mixing macrophage with peony root extract.
The peony root extract provided by the invention can play a role in multiple mechanism dimensions and improve the problem of skin sensitivity.
Drawings
FIG. 1 shows how peony root extract of example 1 promotes Filaggrin (Filaggrin), Loricrin (Loricrin), Ceramide Synthase 3(Ceramide synthsase 3) and very long chain fatty acid-extended protein 4(ELOVL4) in keratinocytes.
FIG. 2 shows the suppression of keratinocyte-produced Thymic Stromal Lymphopoietin (TSLP) by the extract of peony root in example 2.
FIG. 3 shows the inhibition of tumor necrosis factor alpha (TNF-. alpha.) production by macrophages by the extract of peony root of example 3.
FIG. 4 shows the inhibition of Nerve Growth Factor (NGF) produced in keratinocytes by the extract of peony root of example 4.
Detailed Description
The inventor finds that the peony root extract can play a role in repairing skin barriers, reducing cell inflammatory factors, playing a role in relieving and the like on the skin so as to improve sensitive muscles through intensive research. On the basis of this, the present invention has been completed.
As used herein, the "peony root extract" contains phytochemicals such as phenols and phenolic glycosides, monoterpenes and monoterpene glycosides, sterols and their glycosides, and flavones.
As used herein, "skin barrier" refers to a physical barrier, which is a "brick wall structure" formed by a sebum membrane, a cornified corneous envelope, lipids, etc., and has the function of preventing the entry of external harmful substances, irritants, and sunlight, and simultaneously preventing the loss of water. Impaired physical barrier of the skin will cause skin dryness, skin aging, pigmentation and skin sensitivity.
As used herein, "keratinocytes (keratinocytes)" also known as keratinocytes or keratin-forming cells, are the major cellular components that make up the epidermal layer. Keratinocytes at different differentiation stages form the four-layer structure of the epidermal layer of the skin, which is the stratum corneum, the stratum granulosum, the stratum spinosum and the stratum basale from the outside to the inside. The epidermal layer of keratinocytes serves a barrier function.
As used herein, "inflammatory factor" refers to various cytokines involved in inflammatory responses. Mainly comprises tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and the like.
As used herein, "soothing" or "reducing a nerve hyperresponse" are used interchangeably and refer to the inhibition and/or reduction of skin discomfort caused by external stimuli, including, but not limited to, itching, redness, warmth, stinging, etc.
The term "effective amount" is intended to be used for the purpose of strengthening and/or repairing the skin barrier, improving skin sensitivity, etc., and such an amount is capable of strengthening and/or repairing the skin barrier, reducing cytokines and/or providing soothing effects after a suitable period of use.
"composition" refers to a composition that, when applied to an individual (typically a human), is capable of penetrating the skin to induce the desired improvement in skin sensitivity.
As used herein, the term "cosmetically acceptable carrier" refers to a carrier that allows a cosmetic or personal care product to be applied, including various excipients and diluents, which are not themselves essential active ingredients, and which do not have undue toxicity after application. Suitable carriers are well known to those of ordinary skill in the art. A sufficient discussion of cosmetically acceptable excipients can be found in the cosmetic hygiene specifications 2015 edition. Such carriers may include humectants, emulsifiers, thickeners, chelating agents, emollients, and the like in the composition. Such as, but not limited to, water, potassium hydroxide, 1, 2-hexanediol, p-hydroxyacetophenone, ethylhexylglycerin, butylene glycol, panthenol, dipotassium glycyrrhizinate, arginine, glycerin, sodium hyaluronate, propylene glycol, hexylene glycol, glyceryl stearate/PEG-100 stearate, glyceryl caprylate, xanthan gum, betaine, hydroxyethylcellulose, carbomer, disodium EDTA, isomeric hexadecane, isooctyl palmitate, ethylhexyl palmitate, cetostearyl alcohol, cetearyl alcohol, polydimethylsiloxane, citric acid or a salt thereof, behenyl alcohol, beheneth, ceteth, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate, and the like.
The term "administering" as used herein means directly administering an equivalent amount of the extract of the root of peony.
The terms "individual" or "personal" are used herein to refer to a person who can receive the described moutan root extract and/or method for application to the skin.
As used herein, "room temperature" means 15-45 deg.C, preferably 20-35 deg.C.
The present invention provides a method of improving skin sensitivity comprising repairing the skin barrier, reducing inflammatory factors, and/or providing soothing benefits. The method comprises administering a peony root extract and/or a composition comprising a peony root extract.
In one embodiment of the invention, repairing the skin barrier comprises promoting expression of filaggrin, expression of keratinized envelope protein, and expression of long-chain lipid synthesis-related enzymes in keratinocytes; for example, promote the production (including gene expression) of Filaggrin (Filaggrin), Loricrin (Loricrin), Ceramide Synthase 3(Ceramide synthsase 3) and/or ultralong chain fatty acid elongase 4(ELOVL4) in keratinocytes.
In one embodiment of the invention, reducing the inflammatory factor comprises reducing the expression of tumor necrosis factor alpha (TNF- α) and Thymic Stromal Lymphopoietin (TSLP) in skin cells following stimulation.
In one embodiment of the invention, exerting soothing efficacy comprises reducing substance P-induced overexpression of Nerve Growth Factor (NGF).
The peony root extract administered in the present invention is a liquid, and its concentration is between 0.01-3.0mg/mL, such as, but not limited to, 0.01-0.5mg/mL, 0.02-0.7mg/mL, 0.3-2.0mg/mL, 0.05-1.5mg/mL, etc.
In one embodiment of the present invention, the administered peony root extract is the only active ingredient in the composition.
In one embodiment of the present invention, the extract of Paeonia suffruticosa root is obtained from Shanghai Jincheng chemical Co., Ltd
Materials of PAE.
The present invention provides a composition comprising a peony root extract and a cosmetically acceptable carrier, thereby providing various cosmetic or personal care products for application to human skin, including, but not limited to, a makeup cream, a sunscreen cream, a facial cream, an eye cream, an emulsion, a serum, a lotion, a gel, etc. In one embodiment of the present invention, the peony root extract is the only active ingredient in the composition.
The cosmetic or personal care product provided by the present invention contains 0.005-1 wt% of the extract of peony root, such as, but not limited to, 0.02-0.1 wt%, 0.007-0.3 wt%, 0.04-0.9 wt%, 0.06-0.7 wt%, 0.01-0.4 wt%, etc., based on the total weight of the product.
In some embodiments of the present invention, the cosmetic or personal care product is obtained by combining the compositions provided herein with a cosmetically acceptable carrier that can be used to form the aqueous phase. The cosmetically acceptable carrier that may be used to form the aqueous phase includes, but is not limited to, one or more of ethylhexyl glycerin, butylene glycol, glycerin, sodium hyaluronate, and water.
In one embodiment of the present invention, the composition provided by the present invention is mixed with water to form an aqueous phase, and then mixed with a cosmetically acceptable carrier for the oil phase and emulsified to obtain the cosmetic or personal care product. Preferably, the cosmetic or personal care product may be formed by adding preservatives, perfumes, etc. after emulsification and cooling to room temperature.
In another embodiment of the present invention, the cosmetic or personal care product is obtained by adding the composition provided by the present invention after mixing and emulsifying the cosmetically acceptable carrier of the oil phase and the cosmetically acceptable carrier of the water phase. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after emulsification and cooling to room temperature.
In another embodiment of the invention, the cosmetic or personal care product may also be obtained by adding the composition provided by the present invention after homogenization of the aqueous cosmetically acceptable carrier. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after homogenization and cooling to room temperature.
In some embodiments of the invention, the cosmetically acceptable carrier used to form the oil phase includes, but is not limited to, one or more of glyceryl stearate, glyceryl monostearate, glyceryl stearate/PEG-100 stearate complex, isomeric hexadecanes, isooctyl palmitate, ethylhexyl palmitate, cetearyl alcohol, behenyl alcohol, cetostearyl alcohol, ceteth, dimethicone, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate petrolatum, shea butter, squalane, lecithin.
Although numerical ranges and parameters setting forth the broad scope of the invention are approximate, the values set forth in the specific examples are presented as precisely as possible. Any numerical value, however, inherently contains certain standard deviations found in their respective testing measurements. As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean, as considered by those skilled in the art. Except in the experimental examples, or where otherwise expressly indicated, it is to be understood that all ranges, amounts, values and percentages herein used (e.g., to describe amounts of materials, length of time, temperature, operating conditions, quantitative ratios, and the like) are to be modified by the word "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, these numerical parameters are to be understood as meaning the number of significant digits recited and the number resulting from applying ordinary carry notation.
Unless defined otherwise herein, the scientific and technical terms used herein have the same meaning as is commonly understood and used by one of ordinary skill in the art. Furthermore, as used herein, the singular tense of a noun, unless otherwise conflicting with context, encompasses the plural form of that noun; the use of plural nouns also covers the singular form of such nouns.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All features disclosed in this specification may be combined in any combination, provided that there is no conflict between such features and the combination, and all possible combinations are to be considered within the scope of the present specification. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
The main advantages of the invention are: the peony root extract or the composition taking the extract as the only active ingredient provided by the invention can play a role in repairing skin barriers, reducing cell inflammatory factors and reducing excessive reaction of nerves at the same time and improve sensitive muscles.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified. The weight volume percentage units in the present invention are well known to those skilled in the art and refer to, for example, the weight of solute in a 100 ml solution. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1
The peony root extract promotes the production of Filaggrin (FLG), Loricrin (LOR), Ceramide Synthase 3(Ceramide Synthase3, CerS3) and very long chain fatty acid elongase 4 (aggregation of chain fatty acids protein 4, ELOVL4) in keratinocytes
Material
The test system comprises:
the cells used in this test were keratinocytes, lot No.: EP21012001, obtained by cell primary, subculture, Guangdong Boxi Biotech limited.
The main reagents are as follows:
KC2500 broth (guangdong boxi), mtt (sigma), dmso (sigma), PBS (bosch de), rnaioso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara).
The main equipment is as follows:
CO2incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), micro-oscillator (Linbel), enzyme labeling instrument (BioTek), incubator (Tester), fluorescent quantitative PCR instrument (BioRad), common PCRPCR instruments (Bori).
The test substance:
peony root extract was purchased from shanghai jin cheng chem limited under the trade name:
PAE
the control group is cell + KC2500 culture solution
Method
Inoculation:
by 2.8X 105Cell/well inoculation Density cells were plated onto 6 well plates, incubators (37 ℃, 5% CO)2) And incubated overnight.
Preparing liquid:
control group: inoculating cells (blank without any other components, to show the expression level of certain molecules in cells under normal conditions)
Peony root extract: 0.03mg/mL (peony root extract dissolved in DMSO and added into KC2500 culture solution)
Administration:
when the cell plating rate in the 6-hole plate reaches 40% -60%, the medicine is administered in groups, the dosage of each hole is 2mL, each group is provided with 3 multiple holes, and the incubator (37 ℃ and 5% CO)2) Middle incubation for 24 hours
Collecting a sample:
after 24 hours of incubation, the solution was discarded, washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, lysed cells were aspirated, and samples were collected
And (3) gene expression detection:
extracting RNA, reverse transcribing to cDNA, and fluorescent quantitative PCR detection with 2-△△CT method carries out result calculation
And (4) result statistical analysis:
the graph is drawn by using GraphPad Prism Program software, t-test statistical analysis is adopted among groups, p <0.05 indicates that the difference is obvious, and p <0.01 indicates that the difference is extremely obvious
Results
See figure 1.
In keratinocytes, the peony root extract had the effect of promoting the expression of filaggrin (+ 28%), loricrin (+ 14%), ultralong-chain fatty acid elongase 4 (23%) and ceramide synthase 3(+ 11%) genes (p < 0.05).
Filaggrin and loricrin play a positive regulation role in the maturation process of horny layer cells and have the effect of strengthening and toughening the horny cell barrier; the ultralong chain fatty acid protractor protein 4 is responsible for synthesizing long-chain free fatty acid, and the ceramide synthetase 3 is responsible for synthesizing long-chain ceramide from the long-chain free fatty acid. Long chain ceramides are an important component of stratum corneum lipids, responsible for maintaining the function and integrity of the skin barrier.
The results indicate that the peony root extract has the effect of strengthening the skin barrier.
Example 2
Thymic Stromal Lymphopoietin (TSLP) that peony root extract inhibits keratinocyte production
Material
The test system comprises:
the cells used in this test were keratinocytes, lot No.: EP21012001, obtained by cell primary, subculture, Guangdong Boxi Biotech limited.
The main reagents are as follows:
KC2500 broth (guangdong boxi), mtt (sigma), dmso (sigma), PBS (bosch de), rnaioso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara).
The main equipment is as follows:
CO2incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), micro-oscillator (Linbel), enzyme labeling instrument (BioTek), incubator (Tester), fluorescent quantitative PCR instrument (BioRad), general PCR instrument (Bori).
The test substance:
peony root extract was purchased from shanghai jin cheng chem limited under the trade name:
PAE
the control group is cell + KC2500 culture solution
Polyinosinic acid was purchased from Guangdong Boxi Biotech Ltd
Lipopolysaccharide was purchased from Sigma
Dexamethasone Bulganling organism
Experimental methods
Inoculation:
by 2.8X 105Cell/well inoculation Density cells were plated onto 6 well plates, incubators (37 ℃, 5% CO)2) And incubated overnight.
Preparing liquid:
control group: inoculating cells (blank without any other components, to show the expression level of certain molecules in cells under normal conditions)
Stimulus: poly I C + LPS (24. mu.g/mL + 20. mu.g/mL) (formed in combination with DMSO + KC2500 medium) wherein Poly I C (Poly myo-inositol) is an agonist for Toll-like receptor (TLR 3); lipopolysaccharide (LPS) is an agonist of the Toll-like receptor (TLR 4). Reports from PAR2 media nature TRPV3 signalling in keratoctytes. journal of Investigative detail, 140(8), 1524. 1532) and k.h. Lee et al (Lee, k.h., choo, k.a., Kim, j.y., Baek, j.h., Woo, s.y., & Kim, J.W (2011.) cosmetic receptor activator induced by inflammatory cell receptor activator, inflammatory cell receptor activator, tissue receptor activator, tissue receptor activator, tissue receptor, tissue.
Dexamethasone: 0.01 wt% (dissolved in DMSO + KC2500 culture solution)
Peony root extract: 0.06mg/mL (dissolved in DMSO first and then KC2500 culture)
Administration induction:
respectively according to the test scheme, when the cell plating rate in the 6-well plate reaches 40% -60%, carrying out administration induction operation, wherein the administration amount of each well is 2mL, each group is provided with 3 multiple wells, and an incubator (37 ℃, 5% CO)2) Middle incubation for 24 hours
Collecting a sample:
after 24 hours of incubation, the solution was discarded, washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, lysed cells were aspirated, and samples were collected
And (3) gene expression detection:
extracting RNA, reverse transcribing to cDNA, and fluorescent quantitative PCR detection with 2-△△CT method carries out result calculation
And (4) result statistical analysis:
the graph is drawn by using GraphPad Prism Program software, t-test statistical analysis is adopted among groups, p <0.05 indicates that the difference is obvious, and p <0.01 indicates that the difference is extremely obvious
Results
See figure 2.
In keratinocytes, a stimulus induces expression of Thymic Stromal Lymphopoietin (TSLP) through Toll-like receptors on keratinocytes; both the anti-inflammatory drug dexamethasone and the peony root extract significantly inhibited thymic stromal lymphopoietin expression (p < 0.05).
The results indicate that the stimulus increased TSLP expression, inducing neuroinflammation. The peony root extract reduces the effect of irritants, and restores the intracellular neuroinflammation to a level close to that of the placebo (i.e., the level in the normal state).
Example 3
Peony root extract can inhibit tumor necrosis factor alpha (TNF-alpha) produced by macrophage
Material
The test system comprises:
the cells used in this experiment were mouse mononuclear macrophage leukemia cells (RAW264.7) obtained by laboratory subculture.
The main reagents are as follows:
DMEM high-glucose medium (Biosharp), fetal bovine serum (Biosharp), dpbs (Biosharp), mtt (Biosharp), dmso (Biosharp), 0.25% pancreatin (Biosharp).
The main equipment is as follows:
CO2 incubator (Shanghai Boxun, BC-J160), biological safety cabinet (Shanghai, BHC-1300IIA2), enzyme-linked immunosorbent assay (TECAN, Infinite F50), and centrifuge (Hunan Xiang apparatus, H1850R).
The test substance:
peony root extract was purchased from shanghai jin cheng chem limited under the trade name:
PAE
the control group was DMEM (high-glucose) containing 10% fetal bovine serum, which is a culture medium described below
Lipopolysaccharide (LPS) from Sigma
Dexamethasone Bulganling organism
Experimental methods
Inoculation:
cells were plated at 100000 cells/well in 96-well plates, 3 replicates per assay concentration, 37 ℃, 5% CO2The incubator is used for 24 hours plus or minus 2.
Preparing liquid:
control group: inoculating cells (blank without any other components, to show the expression level of certain molecules in cells under normal conditions)
Negative control group: cell culture medium containing LPS (5. mu.g/ml)
Positive control group: medium containing dexamethasone (100. mu.g/mL) and LPS
Test group 1: culture medium containing peony root extract (0.8mg/mL) and LPS (lipopolysaccharide)
Test group 2: culture medium containing peony root extract (1.6mg/mL) and LPS (lipopolysaccharide)
Administration:
after 24 hours +/-2 hours, the culture medium in the 96-well plate is removed, the DPBS is washed once, a test object group 1 and a test object group 2 are added into a test object hole, a positive control group is added into a positive control hole, and a negative control group is added into a negative control hole, wherein each hole is 200 mu l. After the administration, the 96-well plate was placed in CO2Continuously culturing for 6h in the incubator
Collecting a supernatant:
after 24 hours of incubation, the solution was discarded, washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, lysed cells were aspirated, and samples were collected
Detecting the content of TNF-alpha by an ELISA kit:
ELISA detection needs to be carried out according to the instruction of the mouse tumor necrosis factor alpha (TNF-alpha) enzyme-linked immunoassay kit
Results
See figure 3.
On macrophages, Lipopolysaccharide (LPS) induces upregulation of tumor necrosis factor α (TNF α) protein; the anti-inflammatory drug dexamethasone obviously reduces the quantity of tumor necrosis factor alpha; the peony root extract also reduced the amount of this inflammatory factor (by 10% -13%).
The result shows that the expression of TNF-alpha is greatly increased under the stimulation condition, the hormone anti-inflammatory drug dexamethasone pulls the TNF-alpha back to the normal level (but the hormone drug cannot be used for a long time and has side effect), and the peony root extract has no obvious effect of the hormone drug, but also obviously reduces the inflammation.
Example 4
Peony root extract inhibits Nerve Growth Factor (NGF) produced in keratinocytes
Material
The test system comprises:
the cells used in this test were keratinocytes, lot No.: EP21012001, obtained by cell primary, subculture, Guangdong Boxi Biotech limited.
The main reagents are as follows:
KC2500 broth (guangdong boxi), mtt (sigma), dmso (sigma), PBS (bosch de), rnaioso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara).
The main equipment is as follows:
CO2incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), micro-oscillator (Linbel), enzyme labeling instrument (BioTek), incubator (Tester), fluorescent quantitative PCR instrument (BioRad), general PCR instrument (Bori).
The test substance:
peony root extract was purchased from shanghai jin cheng chem limited under the trade name:
PAE
the control group is cell + KC2500 culture solution
Substance P was purchased from Guangdong Boxi Biotech Ltd
Experimental methods
Inoculation:
by 2.8X 105Cell/well inoculation Density cells were plated onto 6 well plates, incubators (37 ℃, 5% CO)2) And incubated overnight.
Preparing liquid:
control group: inoculating cells (blank without any other components, to show the expression level of certain molecules in cells under normal conditions)
Substance P: at a concentration of 20nM
Test group 1: culture medium containing peony root extract (0.03mg/mL) and substance P
Test group 2: culture medium containing peony root extract (0.06mg/mL) and substance P
Administration induction:
respectively according to the test scheme, when the cell plating rate in the 6-well plate reaches 40% -60%, carrying out administration induction operation, wherein the administration amount of each well is 2mL, each group is provided with 3 multiple wells, and an incubator (37 ℃, 5% CO)2) Middle incubation for 24 hours
Collecting a sample:
after 24 hours of incubation, the solution was discarded, washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, lysed cells were aspirated, and samples were collected
And (3) gene expression detection:
extracting RNA, reverse transcribing to cDNA, and fluorescent quantitative PCR detection with 2-△△CT method carries out result calculation
And (4) result statistical analysis:
the graph is drawn by using GraphPad Prism Program software, t-test statistical analysis is adopted among groups, p <0.05 indicates that the difference is obvious, and p <0.01 indicates that the difference is extremely obvious
Results
See figure 4.
Substance P is a nerve signal peptide that induces vasodilation (redness of the skin) and expression of Nerve Growth Factor (NGF). In the experiment, the nerve signal peptide P substance induces the expression of nerve growth factor in keratinocyte, and the peony root extract obviously inhibits the expression of the nerve growth factor under the stimulation condition (P is less than 0.01) and has concentration effect.
The results indicate that the increase of NGF is involved in the path of skin itching, so the peony root extract has a soothing effect.
Example 4
Skin product
Toner
| Name of raw materials | Content (wt%) |
| Water (W) | To 100 |
| Peony root extract | 0.05 |
| Panthenol | 1 |
| 1, 3- |
3 |
| 1, 2-hexanediol | 0.3 |
| Octanoyl hydroximic acid | 0.2 |
| Glycerol | 5 |
| PPG-26-Butaneth-26 | 0.2 |
| Hyaluronic acid | 0.1 |
Emulsion and method of making
| Name of raw materials | Content (wt%) |
| Water (W) | to100 |
| Ethyl hexyl palmitate | 5 |
| Glycerol | 5 |
| Polydimethylsiloxane | 2 |
| |
1 |
| |
1 |
| Hydrogenated polyisobutenes | 4 |
| |
1 |
| Peony root extract | 0.5 |
| |
1 |
| Trimethylpentanediol/adipic acid/ |
1 |
| |
1 |
| 1, 2-hexanediol | 0.5 |
| P-hydroxyacetophenone | 0.3 |
| PEG-40 stearate | 0.5 |
| Polysorbate-60 | 0.5 |
| Triethanolamine | 0.2 |
| Carbomer | 0.2 |
| Xanthan gum | 0.1 |
| EDTA disodium salt | 0.1 |
The foregoing is merely a preferred embodiment of the invention and is not intended to limit the scope of the invention, which is defined by the claims appended hereto, and any other technical entity or method that is encompassed by the claims as broadly defined herein, or equivalent variations thereof, is contemplated as being encompassed by the claims.
Claims (12)
1. Use of extract of peony root for preparing a composition for strengthening and/or repairing skin barrier is provided.
2. Use of peony root extract in preparing composition for improving skin discomfort is provided.
3. Use of peony root extract in preparing composition for improving skin sensitivity is provided.
4. Use according to claim 3, wherein improving skin sensitivity comprises strengthening and/or repairing the skin barrier, reducing inflammatory factors, and having a soothing effect.
5. The use of any one of claims 1 to 4, which comprises 0.01 to 100 wt% of the extract of peony root, based on the total weight of the composition.
6. The use of claim 5, wherein said composition comprises peony root extract and a cosmetically acceptable carrier.
7. The use of claim 5, wherein the composition is a dermatological product.
8. The use according to claim 7, wherein the product form is selected from the group consisting of a solution, a gel, a cream, a liniment, a microemulsion spray, a suspension or an emulsion.
9. The use as claimed in claim 8, wherein the concentration of the peony root extract in the liquid form of the composition is 0.01-3.0 mg/mL.
10. A method for promoting production of filaggrin, loricrin, ceramide synthase3, and/or ultralong chain fatty acid elongase 4 in keratinocytes in vitro, comprising the steps of: mixing the keratinocytes with the extract of peony root.
11. A method of inhibiting in vitro thymic stromal lymphopoietin produced by keratinocytes and/or inhibiting nerve growth factor produced in keratinocytes, comprising the steps of: mixing the keratinocytes with the extract of peony root.
12. A method of inhibiting tumor necrosis factor α produced by macrophages in vitro, comprising the steps of: mixing macrophage with peony root extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111521355.1A CN114028296A (en) | 2021-12-13 | 2021-12-13 | Multi-dimensional skin sensitivity repairing cosmetic component and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111521355.1A CN114028296A (en) | 2021-12-13 | 2021-12-13 | Multi-dimensional skin sensitivity repairing cosmetic component and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028296A true CN114028296A (en) | 2022-02-11 |
Family
ID=80140627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111521355.1A Pending CN114028296A (en) | 2021-12-13 | 2021-12-13 | Multi-dimensional skin sensitivity repairing cosmetic component and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028296A (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120129602A (en) * | 2011-05-20 | 2012-11-28 | 이상록 | The cosmetic composition for moisturizing comprising the mixture of extract of flower of Rhododendron mucronulatum var. lucidum Nakai , Malus pumila var. dulcissima and Magnolia sieboldii |
| KR20150018259A (en) * | 2013-08-09 | 2015-02-23 | 주식회사 엘지생활건강 | Composition for skin moisturizing comprising paeonol |
| FR3033500A1 (en) * | 2015-03-12 | 2016-09-16 | Soliance S A | PROCESS FOR TREATING SENSITIVE IRRITATED SKINS AND PROCESS FOR PREPARING A COMPOSITION USUABLE IN THE TREATMENT OF SENSITIVE IRRITATED SKINS |
| WO2016190661A1 (en) * | 2015-05-26 | 2016-12-01 | 에스케이바이오랜드 주식회사 | Cosmetic composition for inhibiting pruritus and alleviating atopic dermatitis, containing isosecotanapartholide as active ingredient |
| CN106333869A (en) * | 2016-11-02 | 2017-01-18 | 广州美尔生物科技有限公司 | Skin care product having whitening and freckle removing effects and preparation method thereof |
| WO2017069476A1 (en) * | 2015-10-19 | 2017-04-27 | 성균관대학교산학협력단 | Composition for prevention or treatment of liver diseases, containing fraction of moutan radicis cortex extract |
| CN106727168A (en) * | 2017-03-18 | 2017-05-31 | 广州臻颜化妆品有限公司 | With skin care compositions for repairing sensitive skin effect and its preparation method and application |
| JP2019014714A (en) * | 2017-07-06 | 2019-01-31 | アース製薬株式会社 | Anti-inflammatory composition |
| CN111148504A (en) * | 2017-09-26 | 2020-05-12 | 株式会社爱茉莉太平洋 | Skin external composition containing 1,2,3,4,6-penta-O-galloyl- β -D-glucose for moisturizing skin |
| CN111265460A (en) * | 2020-03-13 | 2020-06-12 | 佛山市奥姿美生物科技有限公司 | Skin barrier repair compositions and uses thereof |
| CN112472642A (en) * | 2020-12-04 | 2021-03-12 | 泉后(广州)生物科技研究院有限公司 | Instant soothing cosmetic composition and application thereof |
| CN113304086A (en) * | 2021-05-25 | 2021-08-27 | 云南贝泰妮生物科技集团股份有限公司 | Multi-dimensional barrier repair composition and preparation method thereof |
| CN113491652A (en) * | 2020-04-07 | 2021-10-12 | 美特瑞生物科技(上海)有限公司 | Formula of allergy-relieving skin care product |
| CN113499290A (en) * | 2021-07-15 | 2021-10-15 | 广州环亚化妆品科技有限公司 | Composition with relieving and repairing effects and preparation method and application thereof |
-
2021
- 2021-12-13 CN CN202111521355.1A patent/CN114028296A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120129602A (en) * | 2011-05-20 | 2012-11-28 | 이상록 | The cosmetic composition for moisturizing comprising the mixture of extract of flower of Rhododendron mucronulatum var. lucidum Nakai , Malus pumila var. dulcissima and Magnolia sieboldii |
| KR20150018259A (en) * | 2013-08-09 | 2015-02-23 | 주식회사 엘지생활건강 | Composition for skin moisturizing comprising paeonol |
| FR3033500A1 (en) * | 2015-03-12 | 2016-09-16 | Soliance S A | PROCESS FOR TREATING SENSITIVE IRRITATED SKINS AND PROCESS FOR PREPARING A COMPOSITION USUABLE IN THE TREATMENT OF SENSITIVE IRRITATED SKINS |
| WO2016190661A1 (en) * | 2015-05-26 | 2016-12-01 | 에스케이바이오랜드 주식회사 | Cosmetic composition for inhibiting pruritus and alleviating atopic dermatitis, containing isosecotanapartholide as active ingredient |
| WO2017069476A1 (en) * | 2015-10-19 | 2017-04-27 | 성균관대학교산학협력단 | Composition for prevention or treatment of liver diseases, containing fraction of moutan radicis cortex extract |
| CN106333869A (en) * | 2016-11-02 | 2017-01-18 | 广州美尔生物科技有限公司 | Skin care product having whitening and freckle removing effects and preparation method thereof |
| CN106727168A (en) * | 2017-03-18 | 2017-05-31 | 广州臻颜化妆品有限公司 | With skin care compositions for repairing sensitive skin effect and its preparation method and application |
| JP2019014714A (en) * | 2017-07-06 | 2019-01-31 | アース製薬株式会社 | Anti-inflammatory composition |
| CN111148504A (en) * | 2017-09-26 | 2020-05-12 | 株式会社爱茉莉太平洋 | Skin external composition containing 1,2,3,4,6-penta-O-galloyl- β -D-glucose for moisturizing skin |
| CN111265460A (en) * | 2020-03-13 | 2020-06-12 | 佛山市奥姿美生物科技有限公司 | Skin barrier repair compositions and uses thereof |
| CN113491652A (en) * | 2020-04-07 | 2021-10-12 | 美特瑞生物科技(上海)有限公司 | Formula of allergy-relieving skin care product |
| CN112472642A (en) * | 2020-12-04 | 2021-03-12 | 泉后(广州)生物科技研究院有限公司 | Instant soothing cosmetic composition and application thereof |
| CN113304086A (en) * | 2021-05-25 | 2021-08-27 | 云南贝泰妮生物科技集团股份有限公司 | Multi-dimensional barrier repair composition and preparation method thereof |
| CN113499290A (en) * | 2021-07-15 | 2021-10-15 | 广州环亚化妆品科技有限公司 | Composition with relieving and repairing effects and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 吴敏: "《奶山羊乳腺上皮细胞超长链脂肪酸延伸酶6（ELOVL6）基因的超表达与干扰研究》", 中国优秀硕士学位论文全文数据库（电子期刊）, 28 February 2015 (2015-02-28), pages 9 * |
| 裘炳毅等: "《现代化妆品科学与技术》", 中国医药科学技术出版社, pages: 2137 * |
| 裘炳毅等: "《重大出生缺陷与精准预防》", 31 January 2020, 中国医药科学技术出版社, pages: 2137 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101063299B1 (en) | Cosmetic composition comprising stem cell culture | |
| US20110028404A1 (en) | Composition Comprising Vegetable Peptone for Promoting Stem Cell Proliferation | |
| US20060204471A1 (en) | Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging | |
| CN115252649B (en) | Application of thermophilic bacteria fermentation product in preventing alopecia and/or growing hair, composition and preparation thereof | |
| JPWO2007011066A1 (en) | Fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, ATP production promoter, melanin production inhibitor, skin external preparation | |
| CN110623899A (en) | Rice-derived skin care composition and preparation method thereof | |
| CN114028296A (en) | Multi-dimensional skin sensitivity repairing cosmetic component and application | |
| CN112386655A (en) | Use of phalaenopsis amabilis extract for preparing composition for resisting saccharification and improving skin appearance | |
| US20070286915A1 (en) | Nerve Growth Factor Production Inhibitor and External Preparation for the Skin, Cosmetic, Quasi Drug, Preventive and Remedy for Atopic Dermatitis Containing the Nerve Growth Factor Production Inhibitor | |
| TWI777096B (en) | Use of extract of ginkgo biloba callus tissue for improving skin redness | |
| KR20100055734A (en) | Skin external composition for enhancing skin barrier or moisturizing skin containing 7,3',4'-trihydroxyisoflavone | |
| TWI789553B (en) | Use of hemerocallis fulva linn. extract for manufacturing of a composition for promoting skeletal muscle basal metaboilc rate | |
| CN111184822A (en) | Application of cogongrass rhizome fermentation product in improving gene expression quantity, promoting proliferation of collagen and elastin and improving oxidation resistance | |
| CN113081878B (en) | Combination for synergistically promoting synthesis of hyaluronic acid in skin and application thereof | |
| CN113143782B (en) | Cosmetic composition for improving epidermal aging and application thereof | |
| KR101373714B1 (en) | Cosmetic composition promoting cornified envelope formation | |
| TWI734058B (en) | Use of chimonanthus salicifolius extract for delaying skin cell aging | |
| KR20110101727A (en) | Composition for improving skin wrinkle | |
| CN114010563A (en) | Component with brightening and anti-aging effects and application thereof | |
| WO2022168846A1 (en) | Barrier function improver | |
| TWI712416B (en) | Use of extract of sphagneticola trilobata for anti-inflammation of skin and promoting keratinocyte proliferation | |
| US8012486B2 (en) | Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient | |
| JP2021143141A (en) | Regulatory t-cell inducer | |
| TWI746917B (en) | Use of citrus aurantium flower extract for reducing skin aging and fat content | |
| JP2023099896A (en) | Agent for promoting the production of filaggrin and/or epidermal hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |